Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV
Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV
Chronic hepatitis C is both a virologic and a fibrotic disease, with mortality resulting
 mainly from the complications of cirrhosis and HCC.

 The investigators' aim will be to evaluate the impact on of supplementation with a new
 pharmaceutical complex of silybin-vitamin E-phospholipids in patients with chronic hepatitis
 C treated with Pegylated-Interferon-α2b plus Ribavirin.
Inclusion Criteria:

 -  18 years of age or older,

 -  infection by HCV

 -  under treatment with pegylated interferon 2 alpha and ribavirin

 Exclusion Criteria:

 -  other liver diseases

 -  cancer

 -  severe jaundice

 -  pulmonary and renal chronic diseases

 -  prostatic diseases

 -  autoimmune diseases

 -  diabetes mellitus